Douglas S. Ingram, President & CEO at Sarepta Therapeutics, Inc. (SRPT), bought 39,190 shares at $79.70 ($3.1M) on 2023-11-03, disclosed to the SEC on 2023-11-06.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $78.57 | 10,081 | $792K | 25.5% |
| 2 | $78.57 | 10,081 | $792K | 25.5% |
| 3 | $79.70 | 11,060 | $881K | 28.4% |
| 4 | $80.33 | 3,884 | $312K | 10.0% |
| 5 | $80.33 | 3,884 | $312K | 10.0% |
| 6 | $81.26 | 200 |
| $16K |
| 0.5% |
| Total | $79.25 avg | 39,190 | $3.1M | 100% |
| Filing → |
| SRPT | BUY | 2019-08-12 | $4.0M | — | Filing → |
| SRPT | BUY | 2018-10-30 | $4.0M | — | Filing → |
| SRPT | BUY | 2018-08-16 | $2.0M | — | Filing → |